Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | YBL-006 |
Trade Name | |
Synonyms | YBL006|YBL 006 |
Drug Descriptions |
YBL-006 is a monoclonal antibody that binds to PD-1 (PDCD1) and blocks its interaction with PD-L1 (CD274) and PD-L2 (PDCD1LG2), potentially leading to enhanced immune response and inhibition of tumor growth (Cancer Res 2020;80(16 Suppl):Abstract nr 3367). |
DrugClasses | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 124 |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
YBL-006 | YBL-006 | 0 | 1 |